Two Plus Four: Ruti Aga's Six Years, and the Prescription No Clinic Ever Wrote

Hook

The Athletics Integrity Unit (AIU) statement landed on Thursday. It carried dates, clauses, and one number that gets read first — six years. Ruti Aga, 32, Ethiopian marathoner, winner of the 2026 Tokyo Marathon, three World Marathon Majors runner-up finishes. The ban is dated from 10 September, the same date her provisional suspension began. Add six years: the next time she is eligible to race, she will be 38.

Inside the depth of Ethiopian women's marathon, a 38-year-old with a two-year injury comeback and a doping record on file is not a selection option. On paper this is a six-year suspension; in practice it is the end of a career.

But the six is the last part of the story, not the first. Break the statement down — two years for the substance, four years for the paperwork. What ended this career was not a drug. It was a prescription that was never written in any clinic, issued in the name of a clinic that did not exist, by a man with no medical registration, who then tried to explain it away by claiming he had used an "old prescription pad" from a former workplace.

Let me show you the receipts before the conclusion.

Context

In March, Aga won a half marathon in China. No time from that race appears in the public statement — no splits, no field quality. That absence is itself a signal: the result of a race that is later annulled does not survive in the record anyway. What is on record is that the race was won and that an in-competition test took place. That implies a World Athletics Label-tier race with an elite women's field and routine testing.

The sample contained methylprednisolone. A technical correction is essential here, and it sits at the legal centre of the whole case.

Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, class S9 of the WADA Prohibited List — and that class applies in-competition only, by injection, oral or rectal route. A therapeutic injection taken out of competition is entirely legal. The exception arises only when residues are present in an in-competition sample.

That distinction vanished in the first 24 hours of reporting, which called it a "prohibited steroid." This is not a small slip. Placing a glucocorticoid case in the same queue as an anabolic steroid case distorts the comparison of sanctions itself.

Aga's sporting record stands apart: roughly 2:18:34 for second in Berlin 2026, roughly 2:20:40 for the Tokyo 2026 title, and three Major podium-level finishes. That is the record of a genuinely elite marathoner, and this case does not erase it — only a selected portion of it.

Core

The arithmetic of two and four

The numbers in the statement announce no revolution; they are standard Code arithmetic. Two years for presence — normal for a category of substance where intent is not proven. Four years for tampering — the Code's standard sanction. The sum works.

But a quietly taken decision hides inside that sum: the panel rejected the "no significant fault" mitigation. Had that mitigation been accepted, the presence sanction could have dropped well below two years. The real damage was done not by the four-year penalty but by disqualifying that mitigation.

And why was it disqualified? Because the defence had no genuine medical records. A methylprednisolone injection for a knee injury is routine sports medicine in distance runners — intra-articular or peri-articular, both standard. That clinical explanation is plausible. And that plausibility is precisely what became the verdict: someone who was genuinely treated produces real documents. Someone who has none manufactures them.

Three separate checks, three failures

The chain in the statement can be broken at three independent points. One, the "doctor" who wrote the prescription was a family member with no medical registration. Two, the clinic named on the prescription did not exist — the first level of verification was fake. Three, when the clinic was contacted, it explicitly disowned the "old prescription pad" claim.

Three separate institutions, three separate verifications, all three failed. This is not a mistake. A mistake happens once; the same failure in three places is a process.

And the four-year penalty came not from the document but from the interview. That detail is often read and rarely understood. Statements given in an AIU investigative interview get recorded precisely where documents have already collapsed. Language, translation and pressure — these three points recur in interviews conducted with Ethiopian athletes. This case puts all three back on the table.

The testing-window arithmetic

A road race's in-competition testing window opens at 23:59 the night before the race. The implication is direct: an injection given days earlier can still leave residues on race day and be caught. This was never a case about the "steroid" that got reported; it was a case about dose timing and route. Given at the right time, by the right route, with documentation on file, the same injection stays entirely lawful. The same injection, given at the wrong time without paperwork, became the case.

The knee is the real root

The injury appears in one sentence of the statement. For me that is the heaviest sentence. Chronic knee pathology is a known failure mode in high-volume marathon training. The injury does not heal; the pain gets suppressed, because the cost of stopping is the appearance fee.

At this level a glucocorticoid is the cheapest and most available tool. And where the medicine is cheap, the system managing it gets cheap too. What shows here is the absence of a medical team, not corruption — and that distinction matters. An athlete with no credentialed team physician, no TUE process, and no recorded system holding her injury history turns toward documents, because a document is the only verification tool she has left.

This takes me back to 2026. When the live desk stopped during the pandemic, I wrote a scraper against AFI and state-meet result PDFs — roughly 1,400 documents from 2026 to 2026. The finding was that published 400m split data existed for exactly three Indian meets in a decade. I went looking for a trend and found a hole. Since then I have stopped treating missing data as a gap and started treating it as a subject — who didn't publish, what wasn't measured, why. Aga's case is the other end of that logic: where no recording system exists, people build recording systems. Some honestly, some with a prescription pad.

The age curve at thirty-two

Aga is 32. Ethiopian women's marathon has an entire generation below 2:16. A 2:18–2:20 athlete there is "good," not "indispensable." Six years on, at 38, with a doping record on file, her place in the national selection calculus is zero. This sanction was set not by her speed but by her age and her country's depth. The same six years handed down in a country with less depth would tell a different story.

Two economies colliding

A separate pattern deserves recording. After 2026, Aga's calendar was selective Majors plus Asian label races — few starts, high appearance fees. That is the standard model for a 2:18–2:20 marathoner. The Chinese label circuit is the most lucrative part of that model. And that same circuit is now the AIU's highest-yield testing ground.

The appearance-fee economy and the testing economy are colliding in the same race — and both want the same athlete.

Contrarian Angle

The uncomfortable part arrives here, and I will not soften it.

There is no proven endurance benefit from methylprednisolone. It reduces inflammation, dulls pain, and that is why it is used for knees. It is not a substance that improves marathon times. Six years is not proportionate to the advantage she gained — it is proportionate to the lie she told. In legal terms that is coherent. In sporting terms it looks disproportionate, and that discomfort is legitimate.

The counterfactual on the other side cannot be ignored. Had the knee treatment been genuine, had the route and timing been documented, had the TUE process been followed — there might have been no case at all. This sanction was not delivered by the substance. It was delivered by the moment someone decided that if the real document did not exist, a fake one could be made.

Third, and nobody is saying it: the agent or management that accepted or suggested this document appears nowhere in the statement. The AIU named only the family member. The athlete was punished alone, though a document of this kind is never prepared alone. That is my inference, not a recorded fact — but it is the inference the next stage of any investigation should be asking about.

Fourth, and this one belongs to the media. The first reporting of this case mislabelled the substance class. When you print a glucocorticoid as a steroid, the reader's scale of sympathy shifts too. The spreadsheet was clean. The story was not.

Next Signal

The AIU has moved the centre of its investigations. The question used to be what was found in the sample. Now it is where the paperwork came from. Document verification is the next frontier, and in those East African training clusters where a single informal medical network serves many athletes, the next cases are already sitting in the pipeline.

The question is not how long the next ban will be. The question is whether any federation, in any country, will build a TUE and medical-documentation framework for its runners — or hand that job to the AIU as well, which will do it through sanctions, at the cost of one career at a time.

The next time a 32-year-old runner goes out to race on a sore knee, look at whether there is a doctor beside her or a prescription pad.